Table 1.
Characteristics of kidney transplant recipients with Covid-19
| Characteristics | Total | Hospitalized | Ambulatory |
|---|---|---|---|
| (N = 54) | (n = 39) | (n = 15) | |
| Age (years), median (range) | 57 (29–83) | 59 (29–83) | 55 (31–73) |
| Sex (male), n (%) | 38 (70) | 31 (79) | 7 (47) |
| Race/ethnicity, n (%) | |||
| Caucasian/White | 17 (31) | 11 (28) | 6 (40) |
| Hispanic | 17(31) | 14(36) | 3 (20) |
| Black/African American | 13 (24) | 26(10) | 3 (20) |
| Asian | 6 (11) | 4 (10) | 2 (13) |
| Middle Eastern | 1 (2) | 0 (0) | 1 (7) |
| ABO blood group type, n (%) | |||
| Type A | 15 (28) | 11 (28) | 4 (27) |
| Type B | 8 (15) | 6 (15) | 2 (13) |
| Type AB | 2 (3) | 2 (5) | 0 (0) |
| Type O | 29 (54) | 20 (51) | 9 (60) |
| Smoking history, n (%) | 12 (22) | 8 (21) | 4 (27) |
| BMI, median (IQR) | 28 (18–43) | 27 (18–43) | 29 (18–34) |
| Comorbidities, n (%) | |||
| Diabetes | 16 (30) | 12 (31) | 4 (27) |
| Cardiovascular disease | 19 (35) | 16 (41) | 3 (20) |
| Stroke | 4 (7) | 3 (8) | 1 (7) |
| Pulmonary disease | 8 (15) | 7 (18) | 1 (7) |
| Medications for hypertension | 50 (93) | 37 (95) | 13 (93) |
| ACE inhibitor or ARB | 19 (37) | 12 (32) | 7 (47) |
| Cause of ESRD, n (%) | |||
| Hypertension | 11 (20) | 8 (21) | 3 (20) |
| Diabetes | 14 (26) | 11(28) | 3 (20) |
| Glomerulonephritis | 13 (24) | 11 (28) | 2 (13) |
| Lupus | 2 (4) | 1 (3) | 1 (7) |
| Polycystic kidney disease | 3 (6) | 1 (3) | 2 (13) |
| Other | 11 (20) | 7 (18) | 4 (27) |
| Kidney transplant variables, n (%) | |||
| Transplant type, living donor | 37 (69) | 26 (67) | 11 (73) |
| HLA A, B, DR mismatch, median (range) | 4 (0–6) | 5 (0–6) | 4 (2–6) |
| Donor-specific antibodies at transplant | 15 (28) | 11 (28) | 4 (27) |
| T cell–depleting induction | 39 (72) | 30 (77) | 9 (60) |
| Steroid maintenance, n (%) | 20 (37) | 14(35) | 6 (40) |
| Prior acute rejection episode, n (%) | 4 (7) | 4 (10) | 0(0) |
| Baseline serum creatinine (mg/dL), mean ± SD | 1.52 ± 0.67 | 1.58 ± 0.74 | 1.34 ± 0.41 |
| Viral infections within the past 3 months, n (%) | 12 (22) | 9 (23) | 3 (20) |
| Influenza | 2 | 2 | |
| Coronavirus | 1 | 1 | |
| RSV | 2 | 0 | |
| CMV | 2 | 0 | |
| BKV | 1 | 1 | |
| Other | 2 | 0 |
ARB, angiotensin receptor blocker; HLA, human leukocyte antigen; RSV, respiratory syncytial virus; CMV, cytomegalovirus; BKV, polyomavirus BK.